It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We conducted a pilot study of a potential endoscopic alternative to bariatric surgery. We developed a Natural Orifice Transluminal Endoscopic Surgery (NOTES) gastric bypass with controlled bypass limb length using four new devices including a dedicated lumen-apposing metal stent (GJ-LAMS) and pyloric duodenal exclusion device (DED). We evaluated procedural technical success, weight change from baseline, and adverse events in growing Landrace/Large-White pigs through 38 weeks after GJ-LAMS placement. Six pigs (age 2.5 months, mean baseline weight 26.1 ± 2.7 kg) had initial GJ-LAMS placement with controlled bypass limb length, followed by DED placement at 2 weeks. Technical success was 100%. GJ-LAMS migrated in 3 of 6, and DED migrated in 3 of 5 surviving pigs after mucosal abrasion. One pig died by Day 94. At 38 weeks, necropsy showed 100–240 cm limb length except for one at 760 cm. Weight gain was significantly lower in the pigs that underwent endoscopic bypass procedures compared to expected weight for age. This first survival study of a fully endoscopic controlled bypass length gastrojejunostomy with duodenal exclusion in a growing porcine model showed high technical success but significant adverse events. Future studies will include procedural and device optimizations and comparison to a control group.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Aix-Marseille University, Department of Hepatogastroenterology, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille: Faculty of Medicine, Marseille Cedex 20, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817)
2 Aix-Marseille University, Department of Digestive Surgery, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817); Aix-Marseille University, Centre for Surgical Teaching and Research (CERC), Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817)
3 Brussels Medical Device Center (BMDC), Brussels, Belgium (GRID:grid.5399.6)
4 Boston Scientific Corporation, Endoscopy Division, Marlborough, USA (GRID:grid.418905.1) (ISNI:0000 0004 0437 5539)